Last $45.50 USD
Change Today +2.10 / 4.84%
Volume 26.2K
As of 1:36 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

novo nordisk a/s-b (NONOF) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/18/14 - $49.41
52 Week Low
01/29/14 - $37.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVO NORDISK A/S-B (NONOF)

Related News

No related news articles were found.

novo nordisk a/s-b (NONOF) Details

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

37,978 Employees
Last Reported Date: 02/5/14
Founded in 1925

novo nordisk a/s-b (NONOF) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: kr15.2M
President, Chief Operating Officer and Member...
Total Annual Compensation: kr9.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: kr8.1M
Chief Science Officer, Executive Vice Preside...
Total Annual Compensation: kr8.1M
Chief Information Officer, Executive Vice Pre...
Total Annual Compensation: kr5.5M
Compensation as of Fiscal Year 2013.

novo nordisk a/s-b (NONOF) Key Developments

Novo Nordisk Receives Positive Opinion from the European Regulatory Authorities for Saxenda® (Liraglutide 3 mg) for the Treatment of Obesity

Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda® (liraglutide 3 mg) for the treatment of obesity. Saxenda®, the intended brand name of liraglutide 3 mg, is a once-daily glucagon-like peptide-1 (GLP-1) analogue, with 97% homology to naturally occurring human GLP-1, a hormone involved in appetite regulation. The CHMP positive opinion recommends that Saxenda® will be indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of 30 kg/m2 (obese), or 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. The CHMP positive opinion is based on data from clinical trials of Saxenda®, including the phase 3 SCALETM clinical development programme, which involved more than 5,000 people with obesity (BMI 30 kg/m2), or who were overweight (BMI 27 kg/m2) with comorbidities. The company expected to receive marketing authorisation from the European Commission within two to three months. Subject to the Commission's approval Novo Nordisk expects to launch Saxenda® in several European markets starting in 2015.

Novo Nordisk to Launch Xultophy® (IDegLira) for People with Type 2 Diabetes

Novo Nordisk announced Switzerland as the first country to launch Xultophy® (IDegLira) for people with type 2 diabetes. Xultophy® is the first combination of a basal insulin [Tresiba® (insulin degludec)] and a GLP-1 analogue [Victoza® (liraglutide)]. Xultophy® is administered as a once-daily single injection independently of meals. It is intended for use in adults with type 2 diabetes that are inadequately controlled with oral glucose-lowering treatments when these are used alone or together with basal insulin. For people with type 2 diabetes uncontrolled on basal insulin, Xultophy® has demonstrated a significant 1.9% HbA1c reduction, mean weight loss of 2.7 kg and a low rate of hypoglycaemia (low blood sugar) comparable to insulin degludec. Type 2 diabetes is a progressive disease, which often requires people to initiate and then intensify insulin treatment to achieve or maintain their glycaemic targets over time. Novo Nordisk expects to make Xultophy® available in other countries throughout Europe in 2015.

The Food and Drug Administration Approves Novo Nordisk Diabetes Drug as a Treatment for Obesity

The Food and Drug Administration has approved a Novo Nordisk diabetes drug as a treatment for obesity. It's the first injectable drug approved for weight loss. The drug, liraglutide, will be marketed under the brand name Saxenda for obese adults and for overweight adults who have weight-related health problems like type 2 diabetes, high blood pressure, or high cholesterol.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NONOF:US $45.50 USD +2.10

NONOF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $62.93 USD +0.495
Biogen Idec Inc $360.97 USD +3.44
Bristol-Myers Squibb Co $62.55 USD +0.4801
Eli Lilly & Co $71.78 USD -0.35
Reckitt Benckiser Group PLC 5,500 GBp -60.00
View Industry Companies

Industry Analysis


Industry Average

Valuation NONOF Industry Range
Price/Earnings 26.5x
Price/Sales 7.9x
Price/Book 17.9x
Price/Cash Flow 21.1x
TEV/Sales 6.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVO NORDISK A/S-B, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at